Share
The global US Gene Therapy On Neurological Diseases Market market size was valued at approximately USD 1.2 billion in 2025 and is projected to reach USD 4.5 billion by 2035, growing at a CAGR of 13.8% during the forecast period.
Gene therapy for neurological diseases represents an innovative and burgeoning sector within the healthcare industry. This market encompasses various therapies designed to treat neurological conditions by rectifying defective genes or providing novel genetic material to combat disease progression. The therapies serve as targeted interventions for conditions such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), among others.
This healthcare-driven market is primarily influenced by advancements in gene-editing technologies and the increasing prevalence of neurological disorders. Key stakeholders involved include pharmaceutical companies, research institutions, healthcare providers, and regulatory bodies. These therapies offer transformative potential in shifting the treatment paradigms for complex neurological conditions, thereby having strategic importance in modern medical practices.
| Impact Factor | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Advancements in Gene Editing Technologies | +1.5% | Global | Medium to Long Term |
| Increasing Prevalence of Neurological Disorders | +1.2% | North America, Europe | Short to Medium Term |
| Growing Investment in R&D | +1.0% | Global | Medium Term |
| Regulatory Support for Advanced Therapies | +0.8% | North America, Europe | Short Term |
| Rising Adoption of Personalized Medicine | +0.7% | Global | Long Term |
| Partnerships between Biotech Firms | +0.6% | North America | Medium Term |
| Demand for Non-Invasive Treatment Options | +0.5% | Global | Medium Term |
Key growth drivers include major advancements in gene editing and a rising prevalence of neurological disorders, positively impacting the market trajectory over both short and long-term timeframes.
North America: Holding the largest market share, North America benefits from robust R&D frameworks, leading technological advancements, and proactive investment trends that are accelerating market expansion significantly.
Europe: With stringent regulations focusing on sustainability and safety, Europe showcases growing adoption trends driven by favorable government policies and increasing healthcare expenditure.
Asia Pacific: Poised for rapid growth, Asia Pacific leverages cost-effective manufacturing and burgeoning investment opportunities, making it a hotbed for market development.
Latin America: Emergent opportunities are primarily driven by an expanding healthcare infrastructure and increased awareness regarding neurological therapies.
Middle East & Africa: Although still developing, these regions are seeing gradual market growth facilitated by emerging healthcare investments and an increasing focus on advanced therapy adoption.
Over the next 5β10 years, the US Gene Therapy On Neurological Diseases market is anticipated to witness transformative growth as technology advances and patient demand shifts towards more personalized, efficient treatments. Companies should prioritize segments related to Parkinson's and Huntington's diseases due to high unmet need and favorable regulatory pathways. Strategic investments in R&D and strategic partnerships will be crucial in capturing opportunities in rapidly developing regions like Asia Pacific. Key risks include potential regulatory changes and the need for skilled talent in gene therapy development. Future leaders in this landscape will need to possess competencies in cross-border collaborations, technology integration, and patient-centric innovation.
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Our customers work more efficiently and benefit from
